首页> 外文期刊>Advances in Experimental Medicine and Biology >Gut Microbiota and Heart, Vascular Injury
【24h】

Gut Microbiota and Heart, Vascular Injury

机译:肠道微生物群和心脏,血管损伤

获取原文
获取原文并翻译 | 示例
       

摘要

The gut microbiota plays an important role in maintaining human health. Accumulating evidence has indicated an intimate relationship between gut microbiota and cardiovascular diseases (CVD) which has become the leading cause of death worldwide. The alteration of gut microbial composition (gut dysbiosis) has been proven to contribute to atherosclerosis, the basic pathological process of CVD. In addition, the metabolites of gut microbiota have been found to be closely related to the development of CVD. For example, short-chain fatty acids are widely acclaimed beneficial effect against CVD, whereas trimethylamine-N-oxide is considered as a contributing factor in the development of CVD. In this chapter, we mainly discuss the gut microbial metabolite-involved mechanisms of CVD focusing on atherosclerosis, hypertension, diabetes, obesity, and heart failure. Targeting gut microbiota and related metabolites are novel and promising strategies for the treatment of CVD.
机译:肠道微生物群在维持人类健康方面发挥着重要作用。 积累证据表明,肠道微生物肿瘤和心血管疾病(CVD)之间的亲密关系已成为全世界的死亡原因。 肠道微生物组合物(肠道脱泻)的改变已被证明有助于动脉粥样硬化,CVD的基本病理过程。 此外,已发现肠道微生物酵母的代谢物与CVD的发育密切相关。 例如,短链脂肪酸对CVD广泛受到的有益效果,而三甲胺-N-氧化物被认为是CVD发育中的贡献因素。 在本章中,我们主要讨论CVD的肠道微生物代谢物涉及机制,重点是动脉粥样硬化,高血压,糖尿病,肥胖症和心力衰竭。 靶向肠道微生物和相关的代谢物是治疗CVD的新颖和有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号